Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) EBITDA Margin (2016 - 2025)

Fortress Biotech has reported EBITDA Margin over the past 12 years, most recently at 322.91% for Q4 2025.

  • Quarterly results put EBITDA Margin at 322.91% for Q4 2025, up 51240.0% from a year ago — trailing twelve months through Dec 2025 was 11.01% (up 18902.0% YoY), and the annual figure for FY2025 was 11.1%, up 18910.0%.
  • EBITDA Margin for Q4 2025 was 322.91% at Fortress Biotech, up from 38.63% in the prior quarter.
  • Over the last five years, EBITDA Margin for FBIO hit a ceiling of 322.91% in Q4 2025 and a floor of 27379.78% in Q2 2023.
  • Median EBITDA Margin over the past 5 years was 256.82% (2021), compared with a mean of 3093.25%.
  • Biggest five-year swings in EBITDA Margin: plummeted -1855378bps in 2023 and later surged 2719323bps in 2024.
  • Fortress Biotech's EBITDA Margin stood at 353.95% in 2021, then plummeted by -4141bps to 15009.34% in 2022, then soared by 100bps to 48.9% in 2023, then plummeted by -287bps to 189.48% in 2024, then skyrocketed by 270bps to 322.91% in 2025.
  • The last three reported values for EBITDA Margin were 322.91% (Q4 2025), 38.63% (Q3 2025), and 222.22% (Q2 2025) per Business Quant data.